The experience of bacterial vaginosis can range from an occasional annoyance to a recurring, disruptive problem. Many people notice gray or off-white discharge, a fishy odor, or burning and itching, while others remain asymptomatic. Medical estimates suggest a large portion of people with vaginas will encounter BV at some point in their lives, and certain groups appear to face higher rates. This article unpacks how current science connects BV to sexual contact, who is disproportionately affected, and what that means for testing, treatment, and prevention.
Although BV was long treated as an isolated imbalance rather than an infection spread between people, newer studies have shifted that view. Early research from 1995 hinted at transmission among women who have sex with women, but it did not change routine practice. More recent clinical trials and analyses, including a notable study published in the New England Journal of Medicine, showed that treating partners can significantly reduce recurrence. Those findings are prompting clinicians to rethink how they counsel patients about sexual partners and to consider partner treatment as part of a comprehensive strategy against recurrent BV.
What is bacterial vaginosis and who is affected?
Bacterial vaginosis happens when the normal balance of vaginal bacteria is upset and organisms associated with BV overgrow. Symptoms commonly include abnormal discharge, odor, and irritation, though many people never notice symptoms. For clarity, BV is distinct from yeast infections and from classical sexually transmitted infections, but that distinction is evolving as evidence accumulates. Hormonal shifts, including those caused by medications or hormones such as testosterone, can change the vaginal environment and increase vulnerability to BV. Understanding who is at higher risk helps target prevention and makes clinical care more inclusive.
Is BV sexually transmitted?
Research now supports the conclusion that BV can travel between sexual partners, and that treatment of partners can lower the chance of recurrence. While public guidance from agencies such as the CDC has historically stated that routine partner treatment is not recommended, randomized trials have produced measurable reductions in relapse when partners receive antibiotics. One trial found partner treatment could cut recurrence rates by roughly 30–60% for people with vulvas. These data are reframing BV so clinicians can use sexual health pathways to diagnose and manage it more effectively.
Research gaps and biases
Part of the slow change in thinking stems from long-standing omissions in research and clinical attention. Early studies that hinted at transmission in lesbian communities did not trigger broad changes, and many landmark trials excluded queer and trans people. Providers note that systemic issues like misogyny, transphobia, and homophobia in medicine limited inquiry and validation of patient experiences. As a result, people who reported links between sexual activity and recurrent symptoms were sometimes dismissed, creating both knowledge gaps and barriers to care that only recent inclusive studies are beginning to address.
Treatment, prevention, and equity in care
Standard care for someone diagnosed with BV generally involves antibiotics such as oral or topical metronidazole or clindamycin. Newer approaches encourage evaluation and, where appropriate, treatment of sexual partners. For example, when a person with a vagina has recurrent infections, clinicians may recommend the partner with a penis take oral antibiotics and use topical agents applied to the penile skin. Advocates are pushing for expanded use of expedited partner therapy so partners can receive medication without a separate visit, a strategy that already exists for certain infections in some states but not yet for BV.
Practical prevention steps
While science continues to refine guidance, there are sensible practices people can follow to reduce transmission risk and recurrence. Suggested measures include using barriers such as condoms, washing hands between contact with different partners, cleaning shared sex toys with hot soapy water between users, and laundering sheets and fabrics that may carry genital fluids. Some people use adjuncts like boric acid suppositories after medical treatment to lower recurrence, though these products are often marketed in gendered ways that can create barriers for transmasculine people. Importantly, clinicians stress that BV is a bacterial condition, not a moral failing, and removing stigma helps people seek timely care.